[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
GJ Riely, JW Neal, DR Camidge, AI Spira, Z Piotrowska… - Cancer discovery, 2021 - AACR
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
[HTML][HTML] Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)
JH Cho, SH Lim, HJ An, KH Kim, KU Park… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
The quest to overcome resistance to EGFR-targeted therapies in cancer
CR Chong, PA Jänne - Nature medicine, 2013 - nature.com
All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Y Kobayashi, T Mitsudomi - Cancer science, 2016 - Wiley Online Library
Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19
deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine …
deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine …
[PDF][PDF] Genomic characterization of primary invasive lobular breast cancer
Purpose Invasive lobular breast cancer (ILBC) is the second most common histologic
subtype after invasive ductal breast cancer (IDBC). Despite clinical and pathologic …
subtype after invasive ductal breast cancer (IDBC). Despite clinical and pathologic …